Innovating Tau-Targeted Preclinical Models to Strengthen Translation in Alzheimer’s Drug Discovery

• Developing advanced cell-based tau models to more accurately capture disease-relevant biology, enhancing translational reliability before clinical entry
• Screening novel therapeutic approaches in tau-focused systems to identify mechanisms that directly impact aggregation and pathology, reducing late-stage trial failure
• Aligning preclinical tau biomarkers with clinical endpoints to build stronger continuity across the R&D pipeline, de-risking candidate progression

Speakers:

Jessica Wu

Scientific Director

Biogen